Showing papers by "Serge Resnikoff published in 2023"
TL;DR: In this article , a standardised questionnaire was used to collect medical and socio-economic data among individuals aged 15 years or more in 29 European countries, and the survey included 153,866 respondents aged 50 years old or more.
Abstract: Background Data on population-based self-reported dual vision and hearing impairment are sparse in Europe. We aimed to investigate self-reported dual sensory impairment (DSI) in European population. Methods A standardised questionnaire was used to collect medical and socio-economic data among individuals aged 15 years or more in 29 European countries. Individuals living in collective households or in institutions were excluded from the survey. Results Among 296 677 individuals, the survey included 153 866 respondents aged 50 years old or more. The crude prevalence of DSI was of 7.54% (7.36–7.72). Among individuals aged 60 or more, 9.23% of men and 10.94% of women had DSI. Eastern and southern countries had a higher prevalence of DSI. Multivariable analyses showed that social isolation and poor self-rated health status were associated with DSI with ORs of 2.01 (1.77–2.29) and 2.33 (2.15–2.52), while higher income was associated with lower risk of DSI (OR of 0.83 (0.78–0.89). Considering country-level socioeconomic factors, Human Development Index explained almost 38% of the variance of age-adjusted prevalence of DSI. Conclusion There are important differences in terms of prevalence of DSI in Europe, depending on socioeconomic and medical factors. Prevention of DSI does represent an important challenge for maintaining quality of life in elderly population.
2 citations
TL;DR: In this paper , the authors provide global estimates of the prevalence of corneal blindness and vision impairment in adults 40 years of age and older and examine the burden by age, sex, and geographic region from 1984 through 2020.
TL;DR: This paper investigated the ability of mixture models to describe refractive error distributions and found that mixture models can be used to sample and describe the distribution of refractive errors in populations, which is critical to understanding eye care needs, refractive differences between groups and factors affecting refractive development.
TL;DR: The first series of International Myopia Institute (IMI) white papers was published early in 2019 in response to the growing need for consensus and clinical management guidance on the ever growing, and sometimes conflicting, evidence base around myopia development and management as mentioned in this paper .
Abstract: The first series of International Myopia Institute (IMI) white papers was published early in 2019 in response to the growing need for consensus and clinical management guidance on the ever growing, and sometimes conflicting, evidence base around myopia development and management. The IMI successfully brought together leading academics, clinicians, industry, and other stakeholders to address areas that were agreed to be of importance. Together, more than 85 multidisciplinary experts generously dedicated their time and resources to produce the first series of white papers. In addition to defining and summarizing evidence from experimental animal models, human trials, genetics studies, and the breakthrough technologies of the time for slowing myopia, the white papers identified directions for future research, also establishing definitions and clinical guidelines for application in both myopia-related research and its clinical management, thereby providing researchers and clinicians with both a common language and unified set of goals.1–8 A second series of IMI white papers released in 2021 considered and synthesized other areas of significance, including pathologic myopia, the impact of myopia, risk factors for myopia, roles of accommodation and binocular vision in myopia development and progression, and the prevention of myopia and its progression.9–14 In addition, a digest that provided updates on topics covered in the 2019 papers was published.15 This third series of white papers published in 2023 highlights other key areas of myopia research and management, namely, evidence around onset, progression, and management of myopia in the less typical young adult16 and pediatric (infant and pre-school children less than 5 years of age)17 populations, the role of the choroid in eye growth control and myopia management,18 and a detailed anatomic paper on the “non-pathological” ocular tissue changes observed in moderate to high myopia.19 Emerging evidence for roles of the choroid in both myopia development and myopia control warrants further attention, particularly for clinicians who may be grappling to understand how research findings might translate to clinical practice. A thorough characterization of non-pathological ocular changes in myopia may help researchers to further elucidate the mechanism of axial elongation and better understand associated secondary pathologies. Also included in this series is a report on the results of an international survey of practitioners on myopia management attitudes and strategies in clinical practice.20 This paper reflects on how practices and attitudes regarding myopia management may have changed over the past decade based on other similar, previously published survey results.21,22 The latest results indicate that single vision spectacles and contact lenses are still the most prescribed methods of correction, although clinical activities related to myopia management, including the prescription of myopia control devices and therapies, appear to be increasing. More needs to be done to establish myopia control as the standard of care for progressive myopia around the world. To help stakeholders keep up to date with this fast moving field, new findings across some of the key topics in myopia research since the 2019 digest have been reviewed by experts and summarized as the IMI 2023 digest.23 Consolidation, consensus, and updates on all the latest evidence in the form of these white papers is an important resource for practicing clinicians who may not have the time and resources available to sift through the ever evolving and growing body of evidence to understand how the most recent findings translate to clinical practice and how to implement the most appropriate and effective treatment strategies. All IMI articles and associated infographics, freely available at https://myopiainstitute.org/, serve as tools to help with this process. By highlighting gaps in our current knowledge, they also provide a guide for ongoing and future research. World wide web analytics from the IMI online platform show year on year growth in the number of members, increased new and returning visitors, and greater views and downloads of clinical summaries, white papers, and infographics. The referral pathway, or traffic generated from links provided by third parties, has also grown by over 200% in the past year, indicating the increasing value of the website’s resources in the wider online discussion of myopia. With clinical summaries translated into 15 languages, the platform strives to maintain a truly global audience, as indicated by increased views and downloads in over 187 different countries. By 2050, it is predicted that almost a third of the global population will be myopic, with 10% at levels worse than −5.00 diopters24 and hence at greater risk of sight-threatening complications and visual impairment.25–27 Every diopter matters28 and hence every clinician should be supported and encouraged to introduce evidence-based myopia management to improve the quality of life and wellbeing of their patients, their families, communities, and the broader society.13 We commend all those who are striving to make this change and thank all those who have contributed to these efforts. We also invite all who are willing and interested to join the IMI in these efforts.
TL;DR: In this paper , the authors performed a search of the literature on the management of post-operative trachomatous trichiasis (PTT) and found that only one published trial, the STAR trial in Ethiopia, reported a cumulative PTT rate <10% one year after surgery.